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182, 1200-24To evaluate the short and mid-term results of prostatic artery embolization in patients
with benign prostatic embolization. Retrospective study between March 2009 and June
2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with
symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the
International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of
Erectile Function, prostate volume (PV), prostate-specific antigen (PSA), peak urinary
flow (Qmax), and post-void residual volume (PVR) measurements at 3 and 6 months, 1
year, 18 months, and 2 years after PAE and comparison with baseline values was made.
Technical and clinical successes, as well as poor clinical outcome definitions, were
previously defined. In this review, we evaluate the short and mid-term clinical outcomes
and morbidity of patients treated only with non-spherical polyvinyl alcohol. Six months
after the procedure, the PV decreased about 23%, IPSS changed to a mean value of 11.95
(almost 50% reduction), the QoL improved slightly more than 2 points, the Qmax changed
to a mean value of 12.63 mL/s, the PVR underwent a change of almost half of the
baseline value, and the PSA decreased about 2.3 ng/mL. In the mid-term follow-up and
comparing to the baseline values, we still assisted to a reduction in PV, IPSS, QoL, PVR,
and PSA, and an increase in Qmax. Prostatic Artery Embolization is a safe procedure with
low morbidity that shows good short- and mid-term clinical outcome in our institution.
Tech Vasc Interventional Rad 15:290-293 C 2012 Elsevier Inc. All rights reserved.
KEYWORDS prostate artery, embolization, benign prostatic hyperplasiaBenign prostatic hyperplasia (BPH) has a prevalence ofover 50% in men older than 60 years.1 It is associated
with lower urinary tract symptoms such as nocturia,
urgency and leaking, hesitant, interrupted, and weak uri-
nary stream, and in some patients, sexual dysfunction.2,3
Treatment depends on disease staging. Medical therapy
is usually the first line.4,5 Transurethral resection of the
prostate is the standard treatment. However, it can be- see front matter & 2012 Elsevier Inc. All rights reserved
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and is associated with some complications.6-8 Prostatic
artery embolization (PAE) has been suggested as a safe
and effective alternative procedure, reducing clinical
symptoms and associated with reduction in PV.9–11Materials and Methods
This was a retrospective study between March 2009 and
June 2011 of patients aged 50-85 years (mean 66.8 years
old) that met our inclusion criteria. Our inclusion criteria
were male patients older than 50, with symptomatic BPH
refractory to medical treatment for at least 6 months, with
International Prostate Symptom Score (IPSS)418 points
and/or Quality of Life (QoL)43 and/or peak urinary
flow (Qmax)o12 mL/s and/or with acute urinary reten-
tion. Baseline PV was440 mL with sexual dysfunction or.
PAE in the treatment of BPH 291accepting the risk of developing it after embolization.
Exclusion criteria were malignancy, evaluated by prostatic
digital examination, prostate-specific antigen (PSA), trans-
rectal ultrasound, and biopsy in cases with clinical or
imaging suspicion of malignancy. We also excluded patients
with severe atherosclerosis and tortuosity either in the aortic
bifurcation or internal iliac arteries evaluated by computed
tomographic angiography by our team of interventional
radiologists prior to the embolization and as part of our
preembolization workup. Patients with detrusor failure,
neurogenic bladder, urethral stenosis or bladder diverticu-
lum, or stone with surgical indication were also excluded.
The clinical outcome was evaluated by IPSS, QoL,
International Index of Erectile Function (IIEF), PV, PSA,
Qmax and postvoiding residual volume (PVR) measure-
ments at 3 months, 6 months, 1 year, 18 months and
2 years after PAE. We considered poor outcome after PAE
when 1 criteria was met: IPSSZ20 or reductiono25%
or both, QoLZ4 or reductiono1 or both, Qmax impro-
vemento2.5 mL/s and additional treatments required,
which were either medical or surgical.
All the patients were embolized using the same inter-
ventional technique by the femoral approach, in which
the large majority was embolized with unilateral femoral
approach. Bilateral approach was used in patients with
significant atherosclerosis and tortuosity. The end-point
was slow flow or near stasis with interruption of arterial
flow and prostatic opacification. A subjective pain score
(0-10) was used to assess pain during, immediately after,
and 6-8 hours after the procedure. A score of zero means
no pain and 10 means the worst pain felt. During the
procedure we also registered the total procedure time as
well as the fluoroscopy time.
We considered complications in the clinical situations
that resulted from non-target embolization (related to the
specific procedure) or those general situations that are
possible after any interventional procedure (related to any
interventional procedure). We did not consider complica-
tion situations such as postembolization syndrome, mild
pain, or small hematomas at the puncture site. Exceptions
were made in situations in which the patient required
hospitalization or readmission. Situations were consid-
ered to be minor complications if they were easily
managed ambulatorily and major if they led to prolonged
hospitalization or readmission. The patients were evalu-
ated during the day of the procedure before the discharge,
the day after, and weekly for the first month. At that time
we evaluated the puncture site, clinical signs of possible
ischemic or infectious complications, and the patient’s
pain. Our follow-up protocol included physical, imaging,
and laboratory evaluations. In this paper we evaluate
the short- and mid-term clinical outcomes and morbidity
of patients treated only with non–spherical polyvinyl
alcohol in concentration of 100 mm or 200 mm, or both.
Results
Between March 2009 and June 2011 we included 103
patients older than 50 years with indication of PAEconsidering our criteria. We achieved technical success
in 100 patients (7 unilateral and 93 bilateral emboliza-
tion). In the remaining 3 patients, the procedure was not
possible due to extreme tortuosity and atherosclerosis of
the aortic bifurcation and internal iliac arteries or pro-
static artery origins that made selective catheterization
impossible. Three patients had had a prostatic resection
intervention previously.
During the procedure each patient’s pain ranged from
0 to 10 (mean 1.6). Eighty-two patients did not feel any
pain. Only 1 patient felt pain scored at level 10. After the
procedure this was the only patient who experienced pain
with the medication given according to our medication
protocol.
Sixteen patients had a urinary catheter placed at the
time of evaluation of preembolization due to a history of
urinary retention. All of these patients had their catheter
successfully removed in a maximum time period of 20
days after the procedure. All of the patients had sponta-
neously urinated with no recurrence of urinary retention
in the short follow-up period. At 18 months follow-up
there were 3 patients with urinary retention. In 2 of them
we re-embolized the prostatic arterial supply bilaterally
and the catheter was removed. The third patient had a
prostatectomy.
The procedure times ranged from 25 to 185 minutes
(mean time 83 minutes) and the fluoroscopy times were
7-63 minutes (mean time 24 minutes).
Ninety patients were discharged who did not show any
symptoms during the same day of the procedure and the
remaining group stayed 1 night following the procedure.
During the first week of follow-up evaluation we observed
7 patients with inguinal hematomas. Fourteen patients
had macroscopic hematuria and 6 had hematospermia.
These last 2 situations were self-limited and did not
require any specific treatment or intervention besides oral
hydration. Sixteen patients developed urinary tract infec-
tion confirmed in microbiology examinations and they
were treated with the most suitable antibiotics. Among
these patients, the majority had a urinary catheter prior to
the procedure.
Six patients had transient urinary retention, of which
2 of them required a temporary urinary catheter. Two
patients had balanitis which could be easily managed
with treatment with anti-inflammatory medications
according to our postprocedure protocol. We reported 1
major complication, which was a bladder wall ischemia
that led to an intraluminal necrotic tissue that was
removed surgically and did not require bladder wall
reconstruction. This patient had pain scored 10 in the
pain-subjective evaluation during the procedure.
In the short-term follow-up we have 100 patients at 1
month, 83 patients at 3 months and 62 patients at
6 months. Mid-term follow-up included 29 patients at 1
year, 13 patients at 18 months, and 6 patients at 2 years.
Table 1 shows the mean values of PV, IPSS, QoL, Qmax,
PVR, and PSA, and their range values.
At 3-month follow-up we had 13 patients with
clinical failure. Some of them did not have any clinical
Table 1 Baseline, Mean Values and Range of Evaluated Clinical Parameters
Baseline 1 Month 3 Months 6 Months 12 Months 18 Months 24 Months
PV Mean (mL) 88.0 68.7 67.0 67.8 68.0 72.5 76.0
(Min-Max) 40-269 25-183 19-175 21-170 21-170 26-220 26-127
IPSS Mean 22.8 11.73 10.29 10.85 11.22 10.3 9.3
(Min-Max) 4-35 1-31 1-26 0-29 0-32 0-27 1-20
QoL Mean 4.11 2.26 2.04 1.96 2.01 2.0 2.0
(Min-Max) 2-6 0-6 0-5 0-5 0-5 0-4 0-4
Qmax Mean (mL/s) 8.7 11.6 12.68 12.63 12.9 13.73 14.42
(Min-Max) 1.5-22.9 2.8-30 2.8-30 3.9-29 4-27.5 4-42 4.7-27.6
PVR Mean (mL) 104.9 70.38 60.85 61.1 53.38 77.5 93.54
(Min-Max) 0-439 0-361 0-360 0-361 0-226 12-280 0-439
PSA Mean (ng/mL) 6.4 4.52 4.04 4.71 5.24 5.53 6.24
(Min-Max) 0.25-39.37 0.4-43.8 0.35-26.04 0.35-25.95 0.46-26.79 0.4-16 0.92-14.4
IIEF Mean 18.47 19.61 20.07 20,20 19.76 20.41 17.1
(Min-Max) 0-34 0-33 0-30 0-30 0-31 0-30 0-29
PV, prostatic volume; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, peak urinary flow; PVR, post-void residual
volume; PSA, prostate-specific antigen; IIEF, International Index of Erectile Function; Min, minimum value; Max, maximum value.
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follow-up. All these patients had the same symptoms
after PAE (IPSS was higher than 20 and QoLZ4 points).
Among these clinical failures, 3 had significant prostatic
reduction and 5 had unilateral embolization. Two weeks
after the procedures, we repeated the procedure in
2 patients that had unilateral embolization with good
clinical outcome. So, we reduced the number of clinical
failures to 11 patients in short-term follow-up.
Six months after the procedure the PV decreased about
23%, IPSS changed to a mean value of 11.95 (almost 50%
reduction), the QoL improved slightly more than 2 points,
the Qmax changed to a mean value of 12.63 mL/s, the PVR
underwent a change of almost half of the baseline value,
and the PSA decreased about 2.3 ng/mL (Tables 1 and 2).
In the mid-term follow-up and comparing to the baseline
values, we still assisted to a reduction in PV, IPSS, QoL,
PVR, and PSA, and an increase in Qmax.Discussion
Majority of patients showed a significant clinical improve-
ment with no prostatic medication. In comparison with
other treatments, our results seem to be better than thoseTable 2 Change in % or Absolute Values from the Baseline Value
1 Month 3 Months 6 Mo
PV (% Change) 21.93 23.9 23.
IPSS (Change) 11.07 12.51 11.
QoL (Change) 1.85 2.07 2.
Qmax (% Change) þ33.0 þ45.7 þ45.
PVR (% Change) 32.9 41.99 41.
PSA (% Change) 29.4 36.8 26.
IIEF (Change) þ1.14 þ1.6 þ1.obtained with medical therapy in this group of patients.
The change in IPSS is similar to other minimally invasive
techniques such as transurethral microwave thermo-
therapy and transurethral needle ablation and not sig-
nificantly different compared to those with transurethral
resection of the prostate, although they seem to have
poorer symptom-score improvements.12,13
Most clinical failures were evident at short-term
follow-up. We retrospectively evaluated our clinical fail-
ures and in some cases both sides were well embolized,
with no specific reason for those unsuccessful results.
Patients should be informed about the possibility of
clinical failure after a successful PAE. The procedure
can be repeated in cases that are technically feasible,
which would be a patient with poor clinical outcome who
fulfills the inclusion criteria.
We consider that computed tomographic angiography
is crucial for the selection process, and therefore, for the
results after the procedure. In particular, patients with
severe pelvic arterial occlusive disease or tortuosity can be
excluded on the basis of this preprocedure imaging.
The clinical success cannot be predicted based on PV
itself or with other isolated parameters. Prostates with
same volume reduction can have different clinical out-
comes. We think that the factors that explained thes
nths 12 Months 18 Months 24 Months
0 22.7 17.61 13.64
95 11.58 12.5 13.5
15 2.10 2.11 2.4
2 þ48.2 þ57.8 þ65.7
75 49.11 26.12 10.8
4 18.1 13.9 2.5
73 þ1.29 þ1.94 1.37
PAE in the treatment of BPH 293clinical success are not completely understood and
further studies are needed, with more patients and
multicenter studies.
The general improvement in IIEF may possibly be
explained by the interruption of the prostatic medication
that is normally associated with a deterioration in sexual
function. Further study is necessary to understand this
seemingly paradoxical result with PAE.
There are several limitations in this study: we were not
able to measure IPSS, QoL, and Qmax in the patients with
urinary catheter and so the changes in these parameters
can only be evaluated in other patients; this is a retro-
spective study with the use of polyvinyl alcohol in
concentration of 100 mm or 200 mm or both; and out-
comes should be intrepreted considering that the patients
stopped the previous BPHmedication prior to PAE.
PAE is a safe procedure with low morbidity that shows
good short- and mid-term clinical outcomes in our
institution with no sexual dysfunction.
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